Last updated: January 3, 2025
Sponsor: Duke University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Uterine Cancer
Pelvic Cancer
Endometrial Cancer
Treatment
Transrectal ultrasound (TRUS)
Clinical Study ID
NCT05977621
Pro00113768
Ages 18-90 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Histologically proven invasive primary squamous, adenosquamous, or adenocarcinoma ofthe uterine cervix, (recurrent or medically inoperable) uterine adenocarcinoma.
Treatment plan must include curative-intent definitive radiation that includesbrachytherapy treatments with or without concurrent chemotherapy
Adults ≥ 18 years of age
ECOG Performance Status 0-2
Exclusion
Exclusion Criteria:
- Patients with active rectal bleeding or rectal ulcer
Study Design
Total Participants: 7
Treatment Group(s): 1
Primary Treatment: Transrectal ultrasound (TRUS)
Phase:
Study Start date:
February 07, 2024
Estimated Completion Date:
February 28, 2026
Connect with a study center
Duke Cancer Center
Durham, North Carolina 27710
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.